-
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
Thursday, March 20, 2025 - 2:54pm | 542B. Riley Securities initiated coverage on Wednesday on ArriVent Biopharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical focused on developing cancer treatment. The company’s lead drug candidate, firmonertinib is currently being studied in a global FURVENT Phase 3 trial for first-...
-
B. Riley Shares Plummet 50%, FRG Drama Doesn't Bode Well For Q2: CEO
Monday, August 12, 2024 - 2:26pm | 662B. Riley Financial Inc. (NASDAQ:RILY) shares are currently trading at around $8.08, down more than 52.54% at last check Monday, after reports circulated that its second-quarter earnings would be delayed as regulators probe the Los Angeles-based boutique bank.Trading was temporarily halted at 9:33 a...
-
AMC Shares Tank On APE Conversion Plans: Analysts, Jim Cramer And More Say It's 'A Clearer Path For AMC To Survive'
Monday, August 14, 2023 - 12:21pm | 974Shares of leading movie theater chain AMC Entertainment Holdings Inc (NYSE: AMC) are spiraling down Monday after the latest company update on its stock conversion plan. While shares of AMC Entertainment are falling, its preferred units traded as AMC Preferred Equity Units (NYSE: APE) are...
-
Enphase Energy Eyes Europe For Growth, Analyst Turns Bullish On Prospects: 'Continued Runway For Growth'
Friday, June 30, 2023 - 10:28am | 289Enphase Energy Inc (NASDAQ: ENPH) announced Wednesday it had expanded its distribution partnership with 4blue, a full-service wholesaler of solar and battery systems. While concerns persist around growth in the U.S. residential market, Enphase Energy’s “continued runway for growth...
-
Why Globalstar's Stock Surged 17% Today
Monday, June 21, 2021 - 6:55pm | 194Shares of Globalstar (NYSE: GSAT) traded up more than 17% on Monday after B. Riley initiated coverage with a Buy rating with a price target of $3.25. Globalstar operates a low-Earth orbit satellite constellation network. The satellites are used for phone communications and low-speed...
-
B. Riley Upgrades NeoPhotonics On Strong Non-Huawei Demand
Tuesday, September 1, 2020 - 12:33pm | 316Huawei is now de-risked and demand from non-Huawei customers remains strong, which should diversify NeoPhotonics Corp’s (NYSE: NPTN) customer base and improve its quality of earnings, according to B. Riley. The NeoPhotonics Analyst: Dave Kang upgraded NeoPhotonics from Neutral to Buy, ...
-
JC Penney's Return To Sales Growth Remains Unclear
Wednesday, May 22, 2019 - 12:51pm | 515Shares of J C Penney Company Inc (NYSE: JCP) continued to slump Wednesday after reporting bigger losses than expected and projecting more losses for the rest of the year, keeping sell-side analysts bearish on its prospects, with one analyst even suggesting the shopping mall mainstay is a candidate...
-
Analyst Starts Coverage Of Fannie Mae, Views Common And Preferred Shares As A Call Option
Friday, April 5, 2019 - 11:16am | 474After years of waiting for progress from Washington on housing finance reform, Federal National Mortgage Association (OTC: FNMA) investors aren’t necessarily getting what they had hoped for from Wall Street. The Analyst B. Riley analyst Randy Binner initiated coverage of Fannie Mae with a...
-
Potential Winners And Losers In The Optical Space From The Tariff Dispute
Wednesday, July 18, 2018 - 1:47pm | 453The auto and agriculture industries are getting plenty of headlines related to the international trade war. However, B. Riley analyst Dave Kang says the trade war could have a big under-the-radar impact on the optical components industry as well. What To Know President Trump’s proposed...
-
Wall Street Weighs In On Disney's Q2 Earnings
Wednesday, May 9, 2018 - 3:00pm | 497Walt Disney Co. (NYSE: DIS) reported a big second-quarter earnings beat on Tuesday, although investors don't appear to be too impressed. Earnings of $1.84 per share and revenue of $14.5 billion handily beat expectations, but the stock was trading down 2 percent on Wednesday. Several Wall Street...
-
Novavax Analyst Turns Uber-Bullish, Raises Price Target To $10
Wednesday, January 10, 2018 - 12:53pm | 420Analysts at B. Riley FBR initiated coverage of Novavax, Inc. (NASDAQ: NVAX) on Jan. 5 with a Buy rating and $2.25 price target. Just five days later, the firm turned uber-bullish on the stock. The Analyst George Zavoico maintains a Buy rating on Novavax's stock with a 12-month price target...
-
Tesla-AMD Partnership Likely A 'Modest' Negative For Nvidia, But Its Competitive Moat Still Substantial
Thursday, September 21, 2017 - 11:36am | 459Reports surfaced Wednesday that Tesla Inc. (NASDAQ: TSLA) has partnered with semiconductor company Advanced Micro Devices, Inc. (NASDAQ: AMD) to develop artificial intelligence-based driverless automobile chips. There’s no question a deal with Tesla would be bullish for AMD stock, but NVIDIA...
-
Analysts Sentiment On Nvidia Ahead Of Q2 Earnings
Thursday, August 10, 2017 - 1:17pm | 389With NVIDIA Corporation (NASDAQ: NVDA) due to release its second-quarter results Thursday after the close, investors are pondering whether the best performing stock of 2016 can continue its uncanny string of earnings beats. If Wall Street sell-side sentiment is any indicator, the computer processor...
-
NVIDIA CEO's Keynote At CES Exceeded Expectations
Friday, January 6, 2017 - 8:57am | 396NVIDIA Corporation (NASDAQ: NVDA) CEO Jen-Hsun Huang made several new product and partner announcements at the Consumer Electronics Show on January 4. While the details provided by Huang exceeded expectations, the announcement of the GeForce 1080 Ti product launch is still awaited, B. Riley...
-
Nike's Guidance Remains Aggressive Relative To Futures Orders
Wednesday, December 21, 2016 - 8:38am | 319Nike Inc (NYSE: NKE) reported its Q2 2017 results, with the EPS ahead of the estimate and consensus, driven by increased sales. B. Riley’s Mitch Kummetz reiterated a Neutral rating on the company, with a price target of $56. Nike reported its Q2 2017 EPS at ahead of expectations at $0....